Menyeles (Salbutamol Sulfate, Ipratropium Bromide)

Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, causing relaxation, while ipratropium blocks muscarinic M3 receptors, preventing acetylcholine‑induced constriction. The complementary mechanisms produce synergistic bronchodilation, improving airflow in obstructive lung conditions.

The dosage of Menyeles is individualized by the prescribing clinician based on disease severity, patient age, and response to therapy. The prescriber determines the number of inhalations per day and the timing, following local prescribing guidelines and product labeling.

Safety data for Menyeles in pregnancy and lactation are limited. The product’s pregnancy category is listed as unknown, so it should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To request Menyeles, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Menyeles combines salbutamol with ipratropium, offering both β2‑agonist and anticholinergic actions. Compared with salbutamol alone, the combination can provide greater bronchodilation, especially in COPD, and may reduce the frequency of rescue inhaler use. The dual formulation may also lower the dose needed for each component.

Menyeles should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and excessive heat. Keep the inhaler cap tightly closed when not in use and avoid exposure to direct sunlight.

Menyeles is delivered via a metered‑dose inhaler or nebulizer, as directed by the prescriber. The patient should inhale a measured puff or nebulized dose, hold their breath briefly, and repeat if multiple puffs are prescribed. Proper inhalation technique maximizes drug deposition in the lungs.

Serious adverse events, although rare, include paradoxical bronchospasm, angioedema, and cardiac arrhythmias such as tachyarrhythmia. Patients should seek immediate medical attention if they experience worsening breathing, swelling of the face or throat, or irregular heartbeats after using the product.

Menyeles is contraindicated in individuals with known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. It should also be avoided in patients who have experienced a severe allergic reaction to similar bronchodilators or who have certain cardiac conditions where β2‑agonists are prohibited.